DETAILED ACTION
The examiner for your application at the USPTO has changed. Examiner Abigail VanHorn can be reached at 571-270-3502.
Election/Restrictions
Applicants’ election without traverse of Group I, Glc-NAc, Formula VI, siRNA, the first structure in claim 49 and first species in claim 54 in the reply filed on August 12 2026 is acknowledged. Formula IV is free of prior art. Therefore, the species election with regards to the conjugate formula is withdrawn. Claims 1-8, 47-62, 71 and 74-76 are pending in the application. Claims 4-5 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on August 12 2026. Accordingly, claims 1-3, 6-8, 47-62, 71 and 74-76 are being examined on the merits herein.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
This application claims benefit of 63/431,968 (12/12/2022) as reflected in the filing receipt issued on May 7 2024.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on January 16 2025 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Drawings
Color photographs and color drawings are not accepted in utility applications unless a petition filed under 37 CFR 1.84(a)(2) is granted. Any such petition must be accompanied by the appropriate fee set forth in 37 CFR 1.17(h), one set of color drawings or color photographs, as appropriate, if submitted via the USPTO patent electronic filing system or three sets of color drawings or color photographs, as appropriate, if not submitted via the via USPTO patent electronic filing system, and, unless already present, an amendment to include the following language as the first paragraph of the brief description of the drawings section of the specification:
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
Color photographs will be accepted if the conditions for accepting color drawings and black and white photographs have been satisfied. See 37 CFR 1.84(b)(2).
Thus, he drawings are objected to because they are in color but no petition to accept color drawings filed under 37 CFR 1.84(a)(2) or (b)(2) has been accepted.
Nucleotide and/or Amino Acid Sequence Disclosures
Summary of Requirements for Patent Applications Filed On Or After July 1, 2022, That Have Sequence Disclosures
37 CFR 1.831(a) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.831(b) must contain a “Sequence Listing XML”, as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.831-1.835. This “Sequence Listing XML” part of the disclosure may be submitted:
1. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 via the USPTO patent electronic filing system (see Section I.1 of the Legal Framework for Patent Electronic System (https://www.uspto.gov/PatentLegalFramework), hereinafter “Legal Framework”) in XML format, together with an incorporation by reference statement of the material in the XML file in a separate paragraph of the specification (an incorporation by reference paragraph) as required by 37 CFR 1.835(a)(2) or 1.835(b)(2) identifying:
a. the name of the XML file
b. the date of creation; and
c. the size of the XML file in bytes; or
2. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 on read-only optical disc(s) as permitted by 37 CFR 1.52(e)(1)(ii), labeled according to 37 CFR 1.52(e)(5), with an incorporation by reference statement of the material in the XML format according to 37 CFR 1.52(e)(8) and 37 CFR 1.835(a)(2) or 1.835(b)(2) in a separate paragraph of the specification identifying:
a. the name of the XML file;
b. the date of creation; and
c. the size of the XML file in bytes.
SPECIFIC DEFICIENCIES AND THE REQUIRED RESPONSE TO THIS NOTICE ARE AS FOLLOWS:
Specific deficiency - This application fails to comply with the requirements of 37 CFR 1.831-1.834 because it does not contain a “Sequence Listing XML” as a separate part of the disclosure. A “Sequence Listing XML” is required because the disclosure includes nucleic acid sequences with more than 10 specifically enumerated nucleotides and thus are required to be associated with a SEQ ID NO:. See for example Fig. 22 and 23.
Required response - Applicant must provide:
• A “Sequence Listing XML” part of the disclosure, as described above in item 1. or 2.; together with
o A statement that indicates the basis for the amendment, with specific references to particular parts of the application as originally filed, as required by 37 CFR 1.835(a)(3);
o A statement that the “Sequence Listing XML” includes no new matter as required by 37 CFR 1.835(a)(4)
AND
• A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125 inserting the required incorporation by reference paragraph as required by 37 CFR 1.835(a)(2), consisting of:
o A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);
o A copy of the amended specification without markings (clean version); and
o A statement that the substitute specification contains no new matter.
Specific deficiency - Sequences appearing in the drawings are not identified by sequence identifiers in accordance with 37 CFR 1.831(c). Sequence identifiers for sequences (i.e., “SEQ ID NO:X” or the like) must appear either in the drawings or in the Brief Description of the Drawings.
Required response – Applicant must provide:
Amended drawings in accordance with 37 CFR 1.121(d) inserting the required sequence identifiers;
AND/OR
A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125 inserting the required sequence identifiers (i.e., “SEQ ID NO:X” or the like) into the Brief Description of the Drawings, consisting of:
• A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);
• A copy of the amended specification without markings (clean version); and
• A statement that the substitute specification contains no new matter.
Specification
The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code, see page 71. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01.
Claim Rejections - 35 USC § 112-Scope of Enablement
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claim 67 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement.
The specification, while being enabling for reducing relative sFLT1-i13 mRNA expression with the specifically taught oligonucleotides, does not reasonably provide enablement for a composition for treating a disease or disorder of the kidneys in a patient in need of such treatment comprising any oligonucleotide conjugate. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.
To be enabling, the specification of the patent must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557, 1561 (Fed. Cir. 1993). Explaining what is meant by “undue experimentation,” the Federal Circuit has stated:
The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed to enable the determination of how to practice a desired embodiment of the claimed invention. PPG v. Guardian, 75 F.3d 1558, 1564 (Fed. Cir. 1996).1
The factors that may be considered in determining whether a disclosure would require undue experimentation are set forth by In re Wands, 8 USPQ2d 1400 (CAFC 1988) at 1404 where the court set forth the eight factors to consider when assessing if a disclosure would have required undue experimentation. Citing Ex parte Formal, 230 USPQ 546 (BdApls 1986) at 547 the court recited eight factors:
1) the quantity of experimentation necessary,
2) the amount of direction or guidance provided,
3) the presence or absence of working examples,
4) the nature of the invention,
5) the state of the prior art,
6) the relative skill of those in the art,
7) the predictability of the art, and
8) the breadth of the claims.
These factors are always applied against the background understanding that scope of enablement varies inversely with the degree of unpredictability involved. In re Fisher, 57 CCPA 1099, 1108, 427 F.2d 833, 839, 166 USPQ 18, 24 (1970). Keeping that in mind, the Wands factors are relevant to the instant fact situation for the following reasons:
The nature of the invention, relative skill level, and breadth of the claims
The instant invention is directed to a pharmaceutical composition for treating a disease or disorder of the kidneys in a patient in need of such treatment, comprising a pharmaceutically acceptable carrier and an oligonucleotide conjugate. The oligonucleotide comprises any oligonucleotide which comprises complementarity to a target nucleic acid and a functional moiety that comprises a galactosamine or a derivative thereof.
The complex nature of the claims is greatly exacerbated by the breath of the claims. The claims encompass any oligonucleotide which is complementary to any target nucleic acid to treat any disorder or disease of the kidney.
The relative skill of those in the art is high, that of an MD or PHD. Someone with experience in oligonucleotide design as well as therapeutic treatments.
It is noted that while the recitation for treating a disease or disorder of the kidneys in a patient in need of such treatment is an intended use, the enablement of compositions limited by a particular use must be considered. See In re Vaeck, 947 F.2d 488, 20 USPQ2d 1438 (Fed. Cir. 1991) and In re Gardner, 427 F.2d 786, 166 USPQ 138 (C.C.P.A. 1970). Note: MPEP 2164.01(c).
The amount of direction or guidance provided and the presence or
absence of working examples
The specification provides no direction or guidance for treating any kidney disease or disorder with any oligonucleotide. Due to the vastness of compounds classified as oligonucleotide which has complementarity to a target nucleic acid, one of ordinary skill would undergo undue experimentation in deducing which oligonucleotides and/or target nucleic acids are required to actually treat kidney diseases/disorders within applicant’s scope. Then once figuring out the sequence would have to undergo undue experimentation to determine which ones would actually work.
The working examples of the specification are directed towards synthesis of siRNA duplexes (example 2) and administration of the oligonucleotide conjugates (example 3).
It does not appear that the instant specification discusses specific target nucleic acids. While the specification discusses that exemplary target sequences could be the 5’-UTR or an intronic region and discusses ways to make siRNA as well as length and sequence identity considerations (see pages 37-42). The only sequences are disclosed in Fig. 22-23. Example 3 teaches subcutaneous administration of the oligonucleotides to pregnant mice. The specification directs to Fig. 25-30. Figure 25 merely repeats the dose, route of administration and the model. FIG. 26 shows images of kidneys after treatment with oligonucleotide conjugates comprising a Glu-NAc functional moiety according to embodiments of the present teachings. FIG. 27 shows fluorescence spectroscopy images of kidneys after treatment with oligonucleotide conjugates comprising a Glu-NAc functional moiety according to embodiments of the present teachings. FIG. 28 shows fluorescence spectroscopy images of kidneys after treatment with oligonucleotide conjugates comprising a Glu-NAc functional moiety according to embodiments of the present teachings. FIG. 29 shows fluorescence spectroscopy images of kidneys after treatment with oligonucleotide conjugates comprising a Glu-NAc functional moiety and a graph of the mRNA expression according to embodiments of the present teachings. While this graph shows that TriX-siRNA can reduce the mRNA expression, it isn’t expressly clear what siRNA is being administering. Furthermore, no explanation of what the results actually show is provided. Nor is there any discussion on what kidney disease/disorders are attempting to be treated with these results.
FIG. 30 shows a graph of the Glu-NAc-TEG conjugates silencing of kidney sFLT1 mRNA according to embodiments of the present teachings; These results show a reduction in relative sFLT1-i13 mRNA expression. But nothing establishes that this reduction can be utilized to treat any kidney disease or disorder.
The state and predictability of the art
Matsui et al. (Int. J. Mol Sci, 2022) discusses sFLT-1 in chronic kidney disease. It is stated that sFlt-1 mRNA expression is down regulated in chronic kidney disease (section 4.4). Total sFlt-1 id downregulated in the endothelium in CKD (page 8, first paragraph; Fig. 6-7). This would suggest that administration of siRNA, which would be expected to downregulate sFlt-1 would not necessarily treat CKD.
Zaidi et al. (Journal of Nanobiotechnology, 2023) is directed to engineering siRNA therapeutics challenges and strategies. While siRNA are highly effective at post-transcriptionally suppressing the expression of desired target genes, their in vivo delivery faces significant obstacles such as off-target interactions, determining the optimal administration route, limited circulation half-life, inadequate endosomal escape into the cytosol, renal clearance, and immune evasion. Furthermore, siRNA’s intrinsic characteristics, specifically their potent anionic charge and exceptional hydrophilicity, also render them susceptible to systematic degradation within biological system (page 2). Suggesting that mere synthesis of a siRNA does not necessarily lead to treatment or disease.
The lack of significant guidance from the specification or the prior art with regard to treating any kidney disease utilizing any oligonucleotide makes practicing the scope of the invention unpredictable.
In Genentech Inc. v. Novo Nordisk A/S, 108 F.3d 1361, 1366 Fed. Cir. 1997 states that “a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion” and “patent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable.”
The quantity of experimentation necessary
Because of the known unpredictability of the art, and in the absence of experimental evidence, no one skilled in the art would accept the assertion that any oligonucleotide can be used to treat any kidney disease as inferred by the claim and contemplated by the specification. Accordingly, the instant claims do not comply with the enablement requirement of §112, since to practice the invention claimed in the patent a person of ordinary skill in the art would have to engage in undue experimentation, with no assurance of success.
Claim Rejections - 35 USC § 112-Indefiniteness
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 7-8, 49, 55-62 and 74-75 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 7 as written is vague and indefinite for a couple reasons. Claim 7 recites the oligonucleotide “corresponds to” an antisense oligonucleotide or a siRNA. MPEP 2111.03 discusses transitional phrases. However, “corresponds to” is not recited. The instant specification does not define this term. Thus, the term creates uncertainty to the scope as it is not clear if this is inclusive or open-ended or a closed term. Claim 7 recites an oligonucleotide corresponds to an antisense oligonucleotide or a siRNA. The siRNA comprises a sense strand and an antisense strand which suggests a dsRNA. But then the claim also recites “and a double stranded (ds) RNA. This creates uncertainty as to what “and” is referring to. If it is limiting the siRNA then this is redundant as the claim already recites it is a dsRNA by reciting a sense and antisense strand. Or is the limitation is supposed to be limiting the claimed oligonucleotide.
Claim 8 as currently written is vague and indefinite. The claim depends from claim 7 which recites the oligonucleotide is an antisense oligonucleotide, which the state of the art would say is single-stranded, or a siRNA which as claimed contains both a sense strand and an antisense strand. However, claim 8 recites the functional moiety is linked to the sense strand or to the antisense strand. Therefore, it isn’t clear if the claim is limiting the oligonucleotide to a siRNA or if the limitations with regards to the sense strand do not apply.
Claim 49 as currently written is vague and indefinite. Throughout the specification, drawings and claims are shown how the prolinyl derivative
PNG
media_image1.png
53
85
media_image1.png
Greyscale
is utilized. Specifically the OH and the NH are used as branching point. However, claim 49 includes
PNG
media_image2.png
78
167
media_image2.png
Greyscale
which include S and O in the same position as the NH. The chemical elements S and O cannot have more than two bonds unlike NH. Therefore, it isn’t clear how these prolinyl derivatives serve as branching point. Nowhere in the instant specification is a chemical structure or chemical synthesis which shows how to use
PNG
media_image2.png
78
167
media_image2.png
Greyscale
as branching points. Since they cannot serve as branching point in the same manner as the exemplified
PNG
media_image1.png
53
85
media_image1.png
Greyscale
, this creates uncertainty to the scope of the encompassed compounds.
Claim 55 as currently written is vague and indefinite. Claim 55 depends from claim 47 which refers to formula I which recites A, B, C and Glc-N. Claim 55 however also refers to D and L, which does not appear in claim 47. Therefore, these recitation lack antecedent basis.
Claim 57 as currently written is vague and indefinite. Claim 57 depends from claim 47 which refers to formula I which recites A, B, C and Glc-N. Claim 57, however, also refers to D and L, which does not appear in claim 47. Therefore, these recitation lack antecedent basis.
Claim 59 as currently written is vague and indefinite. Claim 59 depends from claim 47 which refers to formula I which recites A, B, C and Glc-N. Claim 59 however also refers to D and L, which does not appear in claim 47. Therefore, these recitation lack antecedent basis.
Claim 61 as currently written is vague and indefinite. Claim 61 depends from claim 47 which refers to formula I which recites A, B, C and Glc-N. Claim 61, however, also refers to D and L which does not appear in claim 47. Therefore, these recitation lack antecedent basis.
Claims 56, 58, 60, 62 and 74-75 are included in the rejection as they depend on a rejected base claim and they do not clarify the issues.
Claim Rejections - 35 USC § 112-Failure to Further Limit
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claims 60 and 62 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends.
Claim 60 fails to further limit the claim from which it depends. Claim 60 depends from claim 59. Claim 59 recites R is (CH2)2((O(CH2)2))3 and n is 2. However, the structure of claim 60 includes L which is a phosphodiester, that is it includes L other than P-R-P; and it includes 3 B-C-Glc-N groups that is n is 3. Therefore, the structure of claim 60 is broader in scope than the claim from which it depends.
Claim 62 fails to further limit the claim from which it depends. Claim 62 depends from claim 61. Claim 61 recites R is (CH2)2((O(CH2)2))3 or (CH2)12; and n is 2. However, the structure of claim 62 includes L which is a phosphodiester that is it includes L other than P-R-P; and it includes 3 B-C-Glc-N groups that is n is 3. Therefore, the structure of claim 62 is broader in scope than the claim from which it depends.
Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 1-3, 6-8, 47-50, 53-54, 71 and 74-76 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Prakash et al. (WO2014205451).
The instant application claims an oligonucleotide conjugate comprising: i) an oligonucleotide comprising a 5' end and a 3' end, wherein the oligonucleotide comprises complementarity to a target nucleic acid; and ii) a functional moiety that is linked to the oligonucleotide and comprises a glucosamine or a derivative thereof.
Prakash et al. is directed to compositions and methods for modulation of target nucleic acids. Claimed is a conjugate group having the following structure:
PNG
media_image3.png
329
341
media_image3.png
Greyscale
(claim 142). The oligonucleotide as claimed is a double-stranded compound comprising a sense strand and an antisense strand (claim 11). The conjugate group is covalently attached to the 5’-end of the sense strand (claim 113) or the 3’-end of the sense strand (claim 114). As taught are modified ds-siRNAs attached to a GalNAc conjugate which target hApoC III. The sequences include all unmodified as well as modified siRNA which contain 2’-fluoro and 2’-O-methyl nucleotides as well as phosphorothioate linkages (page 115).
Therefore, to arrive at the instantly claimed invention one skilled in the art would merely need to utilize the expressly claimed conjugated with any of the specifically taught double stranded siRNA. Where selection of one named species from a list of alternatives is all that is required to arrive at the instantly claimed subject matter, that species is anticipated. Ex Parte A., 17 USPQ2d 1716 (Bd. Pat. App. & Inter. 1990). See also In re Sivaramakrishnan, 213 USPQ 441 (CCPA 1982). MPEP 2131.02.
Regarding the claimed functional moiety, as set forth in the structure above, the functional moiety contains a glucosamine, specifically an N-acetylglucosamine this corresponds to formula III wherein R1 is H; R2 is C(O)C1alkyl; R3, R4, R5 or R6 are H. This structure corresponds to formula I wherein A is an oligonucleotide, B is prolinyl branching point, C is C(O)(CH2)5 and n is 3.
Claim(s) 1-3, 6-8, 47-50, 53-54, 67, 71 and 74-76 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Freier et al. (WO2015168635).
The instant claims are set forth above.
Freier et al. is directed to a compound that has the following structure:
PNG
media_image4.png
445
404
media_image4.png
Greyscale
(claims 184). As claimed the compound is double-stranded (claim 41). The compound comprises a modified oligonucleotide and a conjugate group which consist of 8 to 80 linked nucleosides complementary to nucleobases of SEQ ID NO: 1 (claim 1). As claimed the nucleotides are useful in kidney disease (claim 262). A composition comprising the compound ant at least one of a pharmaceutically acceptable carrier or diluent (claim 208). As taught the siRNA compounds are double-stranded RNAI compounds. One or both strand may comprise any modification motif described for the ssRNA (pages 74-78).
Therefore, Frier et al. anticipates the claims as it expressly claimed a conjugate comprising a galactosamine (i.e. functional moiety) and a double-stranded RNA which is complementary to a target nucleic acid.
Regarding claims 6 and 8, the modified oligonucleotide is attached at the 5’ end or the 3’ end (page 52, lines 11-15).
Regarding the claimed functional moiety, as set forth in the structure above, the functional moiety contains a glucosamine, specifically an N-acetylglucosamine this corresponds to formula III wherein R1 is H; R2 is C(O)C1alkyl; R3, R4, R5 or R6 are H. This structure corresponds to formula I wherein A is an oligonucleotide, B is prolinyl branching point, C is C(O)(CH2)5 and n is 3.
Regarding claim 67, the oligonucleotides are expressly claimed as treating kidney disease. As claimed is a composition comprising the compound and a carrier.
Regarding claims 74-75, as claimed the modified oligonucleotide include phosphorothioate internucleoside linkage (claim34) and modified sugars (claim 35).
Allowable Subject Matter
Claims 51 and 52 are objected to as being dependent upon a rejected base claim but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. While the prior art, see Prakash et al. (claim 167) and Frier et al. (claim 184) suggest conjugates which contain an L-B-D in addition to the galactosamine, the oligonucleotide is attached through the D which structurally distinguish the instant claims from the prior art.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ABIGAIL VANHORN whose telephone number is (571)270-3502. The examiner can normally be reached M-Th 6 am-4 pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Neil Hammell can be reached on 571-270-5919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ABIGAIL VANHORN/Primary Examiner, Art Unit 1636
1 As pointed out by the court in In re Angstadt, 537 F.2d 498 at 504 (CCPA 1976), the key word is “undue”, not “experimentation”.